Introduction
Before 2010, the American Diabetes Association (ADA) recommended the use of fasting plasma glucose (FPG) test, casual plasma glucose tests if symptoms of hyperglycemia were present, or 75 g oral glucose tolerance tests to diagnose diabetes. 1 Following a consensus report from the International Expert Committee, 2 the ADA recommended the inclusion of the glycated hemoglobin (HbA 1C ) assay as a diagnostic tool in its 2010 Clinical Practice Recommendation. 3 Among the advantages of the HbA 1C assay is that it does not require the patient to fast, thereby potentially providing increased screening opportunities. However, it is widely recognized that HbA 1C assay, FPG, and oral glucose tolerance tests do not perfectly overlap, so the substitution of HbA 1C assay for diagnosis would likely change the composition of the diabetes and at-risk population, which in turn would alter the epidemiology of hyperglycemia. 4, 5 To our knowledge, the population effects of implementing HbA 1C assay for diagnosis of diabetes and for identification of individuals at risk for diabetes has not been reported in an outpatient population.
Preventing type 2 diabetes onset in children is becoming increasingly important because of the dramatic rise in the prevalence of at-risk children and adolescents 6 and the subsequent risk of developing diabetes in adulthood. 7 Furthermore, type 2 diabetes is a growing problem among youth aged 10 to 19 years. 8 The ADA 9 currently recommends that children with a body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) equal to or greater than the 85th percentile for age and sex and with any 2 of these risk factors: family history of type 2 diabetes in first-or second-degree relative, race/ethnicity (Native American, African American, Latino, Asian American, Pacific Islander), signs of insulin resistance, and maternal history of diabetes or gestational diabetes mellitus during the child's gestation should be screened for diabetes starting at age 10 years or at the onset of puberty. Given the rise in type 2 diabetes among youth, however, earlier screening may be appropriate, but data on prevalence of diabetes and at-risk children in their first decade of life is scant.
Our primary objective was to determine the impact of the introduction of the HbA 1C assay for diabetes diagnosis among children and adolescents aged 6 to 17 years. Secondarily, we describe the composition of the population of patients with, and at risk for, diabetes resulting from the differential use of FPG test and HbA 1C assay.
Methods
The study sites were Kaiser Permanente (KP) Hawaii (KPHI) and Kaiser Permanente Northwest (KPNW), 2 groupmodel health maintenance organizations that provide integrated health care to approximately 220,000 members in Hawaii and 475,000 members in the Portland, OR, area. Both KPHI and KPNW maintain similar electronic medical record databases that contain information on all inpatient admissions, pharmacy dispenses, outpatient visits, and laboratory
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credits available for this article -see page 96. If multiple values of a given test were available, we considered any elevated value above the appropriate diagnostic level as indicative of that form of hyperglycemia. BMI percentile was estimated from the charts provided by the Centers for Disease Control and Prevention. 10 We used the mean of all values when multiple BMI percentile measures in a year were available.
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Clinicians at both KP Regions have access to the national guidelines, which track very closely to ADA recommendations. The ADA 9 currently recommends that children with a BMI equal to or greater than the 85th percentile for age and sex and with any 2 of these risk factors: family history of type 2 diabetes in first-or second-degree relative, race/ ethnicity (Native American, African American, Latino, Asian American, Pacific Islander), signs of insulin resistance, and maternal history of diabetes or gestational diabetes mellitus during the child's gestation should be screened for diabetes starting at age 10 years or at the onset of puberty. However, there is no mandated policy and KP clinicians are free to practice medicine in the way they believe best suits their patients, but they are encouraged to consult and follow national guidelines.
Statistical Analysis
All analyses were conducted with SAS software, version 9.3 (SAS Institute, Cary, NC). Within each study site, we compared mean values using Fisher exact tests and proportions or categories using χ 2 tests. We present the results separately for KPHI and KPNW to examine the consistency of the findings across two different geographic locations with a decidedly different mix of race/ethnicity. 
Results
The 2009 and 2012 cohorts were of nearly identical size in both KPNW (~58,000) and KPHI (~26,000) (Table 1) , and the demographic composition of the cohorts in both sites was similar in each year. Mean age was 11.8 years in both KPNW cohorts, and 11.7 years in both KPHI cohorts. In both sites, the percentage of female participants was identical between cohort years (KPNW 51.1%; KPHI 48.9%). In KPNW, the number with a BMI measurement was substantially lower in 2012, but the distribution of BMI percentile was significantly different with a greater proportion in the upper percentiles. The BMI percentile distribution was not significantly different between cohorts in KPHI. About 17% of each KPNW cohort and 85% of each KPHI cohort were of minority race/ethnicity.
In both settings, FPG testing was significantly more common in 2009 compared with 2012, but HbA 1C testing was more common in 2012 ( Table 2 ). The proportion with either test increased from 2.56% to 4.02% in KPNW and from 3.18% to 10.48% in KPHI (p < 0.001 for both sites). The proportion identified as at-risk for diabetes by either test increased significantly in both sites from 2009 to 2012 (KPNW: 0.19% vs 1.34%; KPHI: 0.56% vs 1.77%, p < 0.001 for both sites), but the proportion identified with diabetes was not significantly different in either site. Table 3 displays the characteristics of youth identified as at-risk for diabetes by cohort year and study site. In both KPNW and KPHI, mean age for youth at risk for diabetes declined significantly between 2009 and 2012, owing to a much larger proportion aged 6 to 9 years in 2012 (KPNW: 7% vs 32%; KPHI: 11% vs 39%; p < 0.001 for both sites). In addition, a significantly larger proportion of females were identified in 2012 in both sites (KPNW: 39% vs 55%; KPHI: 35% vs 46%; p < 0.001 for both sites). Following the pattern of the total cohorts, the distribution of BMI percentile shifted significantly at KPNW but not at KPHI among at-risk youth. The proportion at risk for diabetes that was of minority race/ethnicity was not significantly different between cohorts at either site. At KPHI, mean age among those identified with diabetes was higher in 2009 compared with 2012 (13.8 vs 11.5, p = 0.044), but there were no other differences between cohorts in the characteristics of youth identified with diabetes at either site (Table 4) . Table 5 displays the percentage tested with either FPG test or HbA 1C assay, the percentage at risk for diabetes, and the percentage with diabetes for key age, sex, BMI, and racial/ethnic strata. Testing was more common at KPHI, but overall the results were consistent across all strata; similar percentages were found in each cohort year, and similar changes were observed from 2009 to 2012 regardless of the age, sex, BMI, or race/ethnicity strata.
Discussion
Following the addition of the HbA 1C assay
In KPHI, a best practice alert was put in place in 2010, which probably increased screening, and KPNW changed their established best practice alert from FPG test to HbA 1C assay after departmental grand rounds and lectures. At both sites the best practice alert triggers for all 6-to 18-year-olds with BMI equal to or greater than the 85th percentile. So the results at least partially reflect the power of the electronic medical record to enhance clinical care.
Current ADA guidelines recommend screening for diabetes among youth beginning at age 10 years when other risk factors such as overweight/obesity are present. 9 The increased use of the HbA 1C assay resulted in 32% to 39% of youth at risk for diabetes being younger than age 10 years in 2012, compared with 7% to 11% in 2009. A recent study of primarily Hispanic obese adolescents Our study was not limited to obese youth and included a wider age range, thus providing a more comprehensive analysis of the adoption and effectiveness of the HbA 1C assay in overweight and normal weight youth. There are no specific recommendations for the use of HbA 1C assay in the pediatric population, and we hope this article highlights the need for them. The increase in use we observed is probably based on recommendations for adults. If so, our study shows the effect of moving to HbA 1C assay in youth if a universal recommendation were made.
It appears that the ease of using HbA 1C assay increased the number of youth being tested. Despite the increase, however, we did not observe a change in the number of cases identified with diabetes, but we did see a substantial increase in those identified as at risk for diabetes. Whether this means that HbA 1C assay inappropriately identifies individuals or that FPG testing misses patients who should be identified as at risk cannot be determined from these data. In any case, it appears that targeted screening has increased as a result of the use of HbA 1C assay, allowing for greater opportunity to intervene. This is important because targeted intervention is essential for the efficient use of diabetes prevention resources. There is no doubt that lifestyle changes or medication can reduce or delay diabetes onset in adults, [12] [13] [14] [15] but evidence of whether such preventive success applies to youth is scant. One recent study in adolescents (aged 10 to 17 years) at high risk of developing type 2 diabetes showed that a 6-month lifestyle intervention combined with metformin showed a modest weight loss and increased insulin sensitivity, 16 but it was not of sufficient duration to assess risk of diabetes onset. Research is needed to determine effective risk reduction strategies for youth.
As type 2 diabetes becomes increasingly common among younger individuals, the lifetime risk of developing complications will likely rise. However, there is evidence that effective glycemic control early in the course of both type 1 and type 2 diabetes can reduce the 
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risk of microvascular and macrovascular disease. 17, 18 HbA 1C assay is clearly an effective method for identifying future diabetes risk, 19, 20 and being at risk for diabetes is associated with increased prevalence of retinopathy and nephropathy, 21 chronic kidney disease, 22 and cardiovascular disease. 23, 24 Furthermore, these complications are all associated with duration of diabetes. [25] [26] [27] Therefore, in terms of prevention of type 2 diabetes and its complications, early recognition with targeted screening is essential.
We also observed a shift in the sex distribution of those identified as at risk for diabetes following implementation of HbA 1C assay, with substantially more females recognized in 2012 than in 2009. This is not surprising given that FPG identifies more men than women with hyperglycemia, 28 although whether this metabolic difference between sexes applies to youth is unclear. In any case, our results suggest that the risk of diabetes among young females, the likelihood of future gestational diabetes, and the number of pregnancies complicated by existing diabetes may be considerably greater than previously believed.
Our study has several limitations. It is likely that those receiving glucose tests are ordered for youth believed to be more at risk for diabetes, so our results should not be viewed as an outcome of general screening efforts. Whether the proportions we identified as at risk for diabetes or with diabetes represent true prevalence cannot be determined from these observational data. However, our objective was not to estimate prevalence but to assess the impact of introducing the HbA 1C assay as a diagnostic tool. The finding that glucose testing rates are increasing should result in a more representative analysis sample in the future. We did not differentiate between type 1 and type 2 diabetes, a very difficult task when limited to observational data. This might have resulted in disproportionately identifying children with type 1 diabetes. Nonetheless, increased use of HbA 1C assay did not affect diabetes identification but had a marked effect on the size and composition of the atrisk population. Therefore, the inability to distinguish between type 1 and type 2 diabetes is probably negligible. We However, the testing data, which is the main emphasis of this article, are based on whole samples regardless of availability of BMI. Although use of the HbA 1C assay to diagnose diabetes appears to have increased the proportion of youth receiving glycemia tests, other unmeasured factors such as education (of both provider and parent) cannot be ruled out. Last, our data came from two Regions of a comprehensive integrated health system that has excellent information technology support. Whether the testing rates and the resulting proportions we report could be generalized to other settings is unknown. The purpose of this research was to address whether the endorsement of HbA 1C assay for diagnosing diabetes affected the screening, detection, and composition of populations of youth with dysglycemia. Although our data answered that question, whether screening is adequate or not is unknown. Unfortunately, because this was an observational study we cannot determine clinician rationale for testing in either cohort year, nor can we assess whether all who should be screened are being screened. This is a vitally important question that we hope to answer with future research.
In conclusion, the 2010 introduction of the HbA 1C assay to diagnose diabetes appears to have increased the proportion of youth receiving glycemia tests. As a result, many more youth are now being recognized as at risk for developing diabetes, and a greater proportion of them are younger (< age 10 years) and female. This change in the number and composition of at-risk youth has important implications for the delivery of diabetes prevention efforts. v
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